543 related articles for article (PubMed ID: 23837575)
1. Phosphatidylinositol 3-kinases inhibitor LY294002 potentiates the cytotoxic effects of doxorubicin, vincristine, and etoposide in a panel of cancer cell lines.
Badinloo M; Esmaeili-Mahani S
Fundam Clin Pharmacol; 2014 Aug; 28(4):414-22. PubMed ID: 23837575
[TBL] [Abstract][Full Text] [Related]
2. Synergistic augmentation of antimicrotubule agent-induced cytotoxicity by a phosphoinositide 3-kinase inhibitor in human malignant glioma cells.
Shingu T; Yamada K; Hara N; Moritake K; Osago H; Terashima M; Uemura T; Yamasaki T; Tsuchiya M
Cancer Res; 2003 Jul; 63(14):4044-7. PubMed ID: 12874004
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of phosphatidylinositol 3-kinase promotes tumor cell resistance to chemotherapeutic agents via a mechanism involving delay in cell cycle progression.
McDonald GT; Sullivan R; Paré GC; Graham CH
Exp Cell Res; 2010 Nov; 316(19):3197-206. PubMed ID: 20736003
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of the PI3K/Akt pathway increases the chemosensitivity of gastric cancer to vincristine.
Xie X; Tang B; Zhou J; Gao Q; Zhang P
Oncol Rep; 2013 Aug; 30(2):773-82. PubMed ID: 23743572
[TBL] [Abstract][Full Text] [Related]
5. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
6. LY294002 and metformin cooperatively enhance the inhibition of growth and the induction of apoptosis of ovarian cancer cells.
Li C; Liu VW; Chan DW; Yao KM; Ngan HY
Int J Gynecol Cancer; 2012 Jan; 22(1):15-22. PubMed ID: 22080879
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of phosphatidylinositol 3'-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models.
Hu L; Hofmann J; Lu Y; Mills GB; Jaffe RB
Cancer Res; 2002 Feb; 62(4):1087-92. PubMed ID: 11861387
[TBL] [Abstract][Full Text] [Related]
8. Reversal effect of PI3-K inhibitor LY294002 on P-glycoprotein-mediated multidrug resistance of human leukemia cell line K562/DNR and gastric cancer cell line SGC7901/ADR.
Zhang Y; Qu XJ; Liu YP; Yang XH; Hou KZ; Teng YE; Zhang JD
Ai Zheng; 2009 Feb; 28(2):97-9. PubMed ID: 19550116
[TBL] [Abstract][Full Text] [Related]
9. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of phosphatidylinositol 3-kinase-Akt signaling blocks growth, promotes apoptosis, and enhances sensitivity of small cell lung cancer cells to chemotherapy.
Krystal GW; Sulanke G; Litz J
Mol Cancer Ther; 2002 Sep; 1(11):913-22. PubMed ID: 12481412
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy.
Tsurutani J; West KA; Sayyah J; Gills JJ; Dennis PA
Cancer Res; 2005 Sep; 65(18):8423-32. PubMed ID: 16166321
[TBL] [Abstract][Full Text] [Related]
12. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
Urol Int; 2011; 86(3):346-54. PubMed ID: 21273759
[TBL] [Abstract][Full Text] [Related]
13. Phosphatidylinositol 3-kinase inhibitor LY294002 suppresses proliferation and sensitizes doxorubicin chemotherapy in bladder cancer cells.
Wu D; Tao J; Xu B; Qing W; Li P; Lu Q; Zhang W
Urol Int; 2011; 87(1):105-13. PubMed ID: 21597260
[TBL] [Abstract][Full Text] [Related]
14. Synergism of PI3K/Akt inhibition and Fas activation on colon cancer cell death.
Zhu L; Derijard B; Chakrabandhu K; Wang BS; Chen HZ; Hueber AO
Cancer Lett; 2014 Nov; 354(2):355-64. PubMed ID: 25199763
[TBL] [Abstract][Full Text] [Related]
15. GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapy-induced apoptosis.
Beurel E; Kornprobst M; Blivet-Van Eggelpoël MJ; Cadoret A; Capeau J; Desbois-Mouthon C
Int J Oncol; 2005 Jul; 27(1):215-22. PubMed ID: 15942663
[TBL] [Abstract][Full Text] [Related]
16. LY294002 and LY303511 sensitize tumor cells to drug-induced apoptosis via intracellular hydrogen peroxide production independent of the phosphoinositide 3-kinase-Akt pathway.
Poh TW; Pervaiz S
Cancer Res; 2005 Jul; 65(14):6264-74. PubMed ID: 16024628
[TBL] [Abstract][Full Text] [Related]
17. Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells.
Clark AS; West K; Streicher S; Dennis PA
Mol Cancer Ther; 2002 Jul; 1(9):707-17. PubMed ID: 12479367
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of EGFR/PI3K/AKT cell survival pathway promotes TSA's effect on cell death and migration in human ovarian cancer cells.
Zhou C; Qiu L; Sun Y; Healey S; Wanebo H; Kouttab N; Di W; Yan B; Wan Y
Int J Oncol; 2006 Jul; 29(1):269-78. PubMed ID: 16773209
[TBL] [Abstract][Full Text] [Related]
19. Phosphoinositide 3-kinase/Akt pathway plays an important role in chemoresistance of gastric cancer cells against etoposide and doxorubicin induced cell death.
Yu HG; Ai YW; Yu LL; Zhou XD; Liu J; Li JH; Xu XM; Liu S; Chen J; Liu F; Qi YL; Deng Q; Cao J; Liu SQ; Luo HS; Yu JP
Int J Cancer; 2008 Jan; 122(2):433-43. PubMed ID: 17935137
[TBL] [Abstract][Full Text] [Related]
20. Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway.
Nguyen DM; Chen GA; Reddy R; Tsai W; Schrump WD; Cole G; Schrump DS
J Thorac Cardiovasc Surg; 2004 Feb; 127(2):365-75. PubMed ID: 14762343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]